Drug Database
Back to search

Poland· PL-100368518

Auroverin MR

A mebeverine product containing mebeverini hydrochloridum, registered in Poland by Aurovitas Pharma Polska Sp. z o.o.. The same ATC class is registered in 13 of our 19 countries.

ATC A03AA04

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAuroverin MRATCA03AA04REGISTER NO.PL-100368518PACKS LISTED7CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about mebeverini hydrochloridumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Mebeverine is registered in 13 of 19 countries.

Countries holding a registration under ATC A03AA04 (mebeverine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search mebeverine products by name

Mebeverine · ATC A03AA04

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of mebeverine costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), the median price runs from $0.20 in France to $1.31 in Switzerland — a ×6.5 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Mebeverine · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1.31
  • FR France$0.20
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Mebeverini hydrochloridum
Manufacturer
Aurovitas Pharma Polska Sp. z o.o.
Country
Poland (PL)
ATC code
A03AA04
ATC class
Mebeverine
Defined daily dose
0.4 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 7

  • gtin
    05909991340902
  • gtin
    05909991340919
  • gtin
    05909991420949
  • gtin
    05909991495459
  • gtin
    05909991495466
  • gtin
    05909991495473
  • gtin
    05909991495480

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Mebeverine in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mebeverine products

Authorised across Europe · EMA

The same active substance is authorised in 25 EEA countries. Names it is sold under:

  • Austria · Colofac, Colofac Retard
  • Belgium · Duspatalin, Duspatalin Retard
  • Bulgaria · Дуспаверин, Дуспаталин
  • Cyprus · Medoverine, Spasverin
  • Czechia · Duspatalin Retard
  • Germany · Duspatal, Duspatal Retard
  • Denmark · Duspatalin Retard
  • Estonia · Mebeverine Sanoswiss
  • Spain · Duspatalin, Mebeverina Tarbis
  • France · Duspatalin, Mebeverine Zentiva
  • United Kingdom (Northern Ireland) · Aurobeverine Mr, Boots Ibs Symptom Relief
  • Greece · Duspatalin
  • Croatia · Colospa Retard, Rudakol
  • Ireland · Colofac, Mebeverine Hydrochloride Azure Pharmaceuticals
  • Iceland · Duspatalin Retard
  • Italy · Duspatal
  • Lithuania · Duspatalin, Mebeverine Sanoswiss
  • Luxembourg · Duspatalin, Duspatalin Retard
  • Latvia · Duspatalin, Mebeverine Sanoswiss
  • Malta · Colofac Retard, Mebeverine Hydrochloride Aspire Pharma (Malta)
  • Netherlands · Duspatal, Duspatal Retard
  • Portugal · Duspatal Retard, Mebeverina Aristo
  • Romania · Colospasmin, Duspatalin
  • Slovenia · Rudakol
  • Slovakia · Duspatalin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/421f025b-4502-481a-b072-73c720c58b70
GET /v1/drugs/421f025b-4502-481a-b072-73c720c58b70?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki o zmodyfikowanym uwalnianiu, twarde",
  "source": "urpl",
  "strength": "200 mg",
  "packaging": "05909991340902 ¦ Rp ¦ 123879\n30 kaps.\n05909991340919 ¦ Rp ¦ 123880\n60 kaps.\n05909991420949 ¦ Rp ¦ 134982\n250 kaps.\n05909991495459 ¦ Rp ¦ 146719\n90 kaps.\n05909991495466 ¦ Rp ¦ 146720\n50 kaps.\n05909991495473 ¦ Rp ¦ 146721\n20 kaps.\n05909991495480 ¦ Rp ¦ 146722\n100 kaps.",
  "substance": "Mebeverini hydrochloridum 200 mg",
  "common_name": "Mebeverini hydrochloridum",
  "pl_product_id": "100368518",
  "pozwolenie_nr": "24186",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about mebeverine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console